Literature DB >> 7480427

Saccadic abnormalities in psychotic patients. I. Neuroleptic-free psychotic patients.

T J Crawford1, B Haeger, C Kennard, M A Reveley, L Henderson.   

Abstract

Most of the previous research reporting abnormalities of rapid re-fixation eye movements (saccades) in patients with schizophrenia has used patients receiving neuroleptic medication. In this study non-neuroleptically medicated schizophrenics were compared with other psychiatric patients using a variety of saccadic paradigms to determine the specificity of saccadic dysfunction. The patient groups consisted of schizophrenics (N = 18), bipolar affectives (N = 18), anxiety neurotics (N = 10) and normal controls (N = 31), none of whom had received neuroleptic medication for the preceding 6 months. Four behavioural paradigms, reflexive, predictive, remembered and ANTI were used to elicit saccades. The primary abnormality in the schizophrenic group was a significantly increased rate of distractibility in the ANTI (saccades made towards the target rather than in an opposite direction) and REM (saccades made prior to the imperative cue) paradigms. The major neuropsychological variable predictive of these errors was Wisconsin card sort perseverative errors. These data, in conjunction with findings from previous neurological research, would seem to provide converging evidence towards dysfunction of prefrontal cortex in schizophrenia.

Entities:  

Mesh:

Year:  1995        PMID: 7480427     DOI: 10.1017/s0033291700033389

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  28 in total

1.  The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: empirical findings and interpretative considerations.

Authors:  Deborah L Levy; Nancy R Mendell; Philip S Holzman
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

2.  Predictive saccades are impaired in biological nonpsychotic siblings of schizophrenia patients.

Authors:  Isabelle Amado; Steffen Landgraf; Marie-Chantal Bourdel; Sabinien Leonardi; Marie-Odile Krebs
Journal:  J Psychiatry Neurosci       Date:  2008-01       Impact factor: 6.186

Review 3.  Eye tracking dysfunction in schizophrenia: characterization and pathophysiology.

Authors:  Deborah L Levy; Anne B Sereno; Diane C Gooding; Gilllian A O'Driscoll
Journal:  Curr Top Behav Neurosci       Date:  2010

4.  Improved antisaccade performance with risperidone in schizophrenia.

Authors:  J G Burke; M A Reveley
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

5.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

Review 6.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

Review 7.  The tell-tale tasks: a review of saccadic research in psychiatric patient populations.

Authors:  Diane C Gooding; Michele A Basso
Journal:  Brain Cogn       Date:  2008-10-23       Impact factor: 2.310

8.  Response suppression deficits in treatment-naïve first-episode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression.

Authors:  Margret S H Harris; James L Reilly; Michael E Thase; Matcheri S Keshavan; John A Sweeney
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

9.  Impaired control of the oculomotor reflexes in Parkinson's disease.

Authors:  Martijn G van Koningsbruggen; Tom Pender; Liana Machado; Robert D Rafal
Journal:  Neuropsychologia       Date:  2009-06-26       Impact factor: 3.139

10.  Preattentional and attentional cognitive deficits as targets for treating schizophrenia.

Authors:  David L Braff; Gregory A Light
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.